• T-Therapeutics closed an oversubscribed $133 million Series B financing.
• Advent Life Sciences and British Business Bank co-led the round, with participation from existing investor Sofinnova Partners alongside other investors.
• The biotechnology company develops T cell receptor-based therapeutics for cancer and autoimmune diseases.
• Proceeds will fund two lead TCR-CD3 bispecific programs through clinical proof of concept in cancer and autoimmune diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sofinnova Partners SAS published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.